Citius Oncology

Citius Oncology FCF Yield

The Free Cash Flow Yield of Citius Oncology (CTOR) as of Nov 22, 2026 is -9.01 %. In the previous year, Free Cash Flow Yield was 0.21 % — a change of -4,446.73% (lower).

FCF Yield

-9.01 %

YoY

-4,446.73%

Last updated:

Free Cash Flow Yield of Citius Oncology is 2025 -9.01 % . Free Cash Flow Yield of Citius Oncology was 2024 0.21 % . It decreases by -4,446.73% lower compared to the previous year.

The Citius Oncology FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2022
-0.08 USD
Jan 1, 2023
-0.99 USD
Jan 1, 2024
0.21 USD
Jan 1, 2025
-9.01 USD
The Citius Oncology FCF Yield history
YEARFCF YieldYoY
-9.01 %-4,446.73%
0.21 %-121.01%
-0.99 %+1,153.56%
-0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

Free Cash Flow Yield of Citius Oncology is -9.01 % in 2025.

Free Cash Flow Yield of Citius Oncology changed from 0.21 % to -9.01 %, representing a -4,446.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Citius Oncology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Citius Oncology

All Key Metrics — Citius Oncology